• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.

作者信息

Ding Kaibo, Peng Zhongsheng, Liu Dujiang, Xu Yanjun

机构信息

Department of Medical Thoracic Oncology, Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, No. 1 East Banshan Road, Gongshu District, Hangzhou, 310022, Zhejiang, China.

Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, Zhejiang, China.

出版信息

J Transl Med. 2024 Aug 14;22(1):761. doi: 10.1186/s12967-024-05522-y.

DOI:10.1186/s12967-024-05522-y
PMID:39143613
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11323653/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c41e/11323653/de7578f2f534/12967_2024_5522_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c41e/11323653/de7578f2f534/12967_2024_5522_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c41e/11323653/de7578f2f534/12967_2024_5522_Fig1_HTML.jpg

相似文献

1
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.Sunvozertinib克服携带EGFR外显子18 DelE709_T710insD突变的肺腺癌对阿法替尼和奥希替尼的耐药性。
J Transl Med. 2024 Aug 14;22(1):761. doi: 10.1186/s12967-024-05522-y.
2
Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.在一名患有EGFR L718Q突变的非小细胞肺癌患者中使用阿法替尼解决对奥希替尼治疗的耐药性
Clin Lung Cancer. 2020 Jul;21(4):e258-e260. doi: 10.1016/j.cllc.2019.12.002. Epub 2020 Jan 23.
3
Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.阿法替尼治疗携带外显子 18 delE709_T710insD 突变的肺腺癌的疗效。
Jpn J Clin Oncol. 2019 Aug 1;49(8):786-788. doi: 10.1093/jjco/hyz086.
4
EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.EGFR外显子18 DelE709_T710insD作为晚期EGFR外显子18 E709H肺腺癌对阿法替尼获得性耐药的机制
J Thorac Oncol. 2018 Jun;13(6):e93-e95. doi: 10.1016/j.jtho.2018.01.006.
5
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.基于液体活检的方法鉴定 EGFR T790M 突变介导的对阿法替尼治疗的耐药性，在晚期 EGFR 突变阳性 NSCLC 患者中，并随后对奥希替尼的反应。
Target Oncol. 2019 Feb;14(1):75-83. doi: 10.1007/s11523-018-0612-z.
6
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab.阿法替尼联合贝伐珠单抗治疗奥希替尼耐药肺腺癌伴 EGFR 外显子 18 突变（G719S）一例
Invest New Drugs. 2021 Feb;39(1):232-236. doi: 10.1007/s10637-020-00966-7. Epub 2020 Jun 18.
7
Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib.奥希替尼成功治疗携 EGFR 外显子 20 插入（A763_Y764insFQEA）突变的肺腺癌晚期复发。
Cancer Genet. 2021 Aug;256-257:57-61. doi: 10.1016/j.cancergen.2021.04.001. Epub 2021 Apr 10.
8
Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.肺腺癌中携带 EGFR T751I759delinsS 突变的阿法替尼和奥希替尼治疗：一例报告。
Thorac Cancer. 2021 Dec;12(24):3429-3432. doi: 10.1111/1759-7714.14215. Epub 2021 Nov 2.
9
EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report.奥希替尼治疗 EGFR 外显子 18 delE709_T710insD 突变的 IV 期非小细胞肺癌 1 例报告
Anticancer Drugs. 2024 Aug 1;35(7):638-640. doi: 10.1097/CAD.0000000000001605. Epub 2024 Mar 15.
10
Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.一名患有罕见表皮生长因子受体（EGFR）突变的肺腺癌患者在对奥希替尼产生获得性耐药后发生鳞状细胞癌转化。
J Formos Med Assoc. 2020 Sep;119(9):1439-1441. doi: 10.1016/j.jfma.2019.12.017. Epub 2020 Mar 12.

引用本文的文献

1
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR Exon 20 S768I Mutant Lung Adenocarcinoma: A Case Report and Review of the Literature.并发TP53突变促进EGFR外显子20 S768I突变型肺腺癌的耐药进化：一例报告及文献复习
Case Rep Oncol. 2025 Jan 9;18(1):220-230. doi: 10.1159/000543453. eCollection 2025 Jan-Dec.

本文引用的文献

1
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.Amivantamab 联合 lazertinib 对比奥希替尼用于具有高风险疾病生物标志物的一线治疗 EGFR 突变型晚期非小细胞肺癌：MARIPOSA 的一项二次分析。
Ann Oncol. 2024 Sep;35(9):805-816. doi: 10.1016/j.annonc.2024.05.541. Epub 2024 Jun 26.
2
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.舒沃替尼用于中国铂类经治的局部晚期或转移性非小细胞肺癌及表皮生长因子受体第20外显子插入突变患者（WU-KONG6）：单臂、开放标签、多中心、2期试验
Lancet Respir Med. 2024 Mar;12(3):217-224. doi: 10.1016/S2213-2600(23)00379-X. Epub 2023 Dec 12.
3
COSMIC: somatic cancer genetics at high-resolution.COSMIC：高分辨率体细胞癌遗传学
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783. doi: 10.1093/nar/gkw1121. Epub 2016 Nov 28.
4
Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer.酪氨酸激酶抑制剂对非小细胞肺癌中罕见的E709X表皮生长因子受体突变的疗效
Onco Targets Ther. 2016 Oct 11;9:6137-6145. doi: 10.2147/OTT.S118071. eCollection 2016.